Nucleoside

Type: Keyphrase
Name: Nucleoside
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Hepatitis B Treatment

Nucleoside/Nucleotide Analogues Interferons Treatment Decisions Investigational Medications Hepatitis B is an infection of the liver caused by the hepatitis B virus (HBV). Hepatitis B may cause people to become very ill for several weeks. These patients ... [Published eMedicine Health - 4 hours ago]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Supporting activities of daily living

The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its ... [Published Free Patents Online - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 1 reports

Forced mutations doom HIV

Fifteen years ago, MIT professor John Essigmann and colleagues from the University of Washington had a novel idea for an HIV drug. They thought if they could induce the virus to mutate uncontrollably, they could force it to weaken and eventually die ... [Published MIT News feed - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 2 reports

Findings from University of Alabama Provides New Data about Biochemical Parasitology (Isolation and substrate specificity of an adenine nucleoside...

Findings from University of Alabama Provides New Data about Biochemical Parasitology (Isolation and substrate specificity of an adenine nucleoside phosphorylase from adult Schistosoma mansoni) By a News Reporter-Staff News Editor at Life Science Weekly ... [Published Wall Street Business Network - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Research Conducted at School of of Chemistry and Biochemistry Has Provided New Information about Prebiotics (Spontaneous prebiotic formation of a...

Research Conducted at School of of Chemistry and Biochemistry Has Provided New Information about Prebiotics (Spontaneous prebiotic formation of a ?-ribofuranoside that self-assembles with a complementary heterocycle)By a News Reporter-Staff News Editor ... [Published HispanicBusiness.com - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA potential diagnostics tools

This invention relates to n-alkylated synthetic nucleosides and phosphoramidites of high regio-specific purity and stability and for selective deprotection of the protecting group in oligonucleotides for the purpose of synthesis of high purity selectively ... [Published Free Patents Online - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase

1 Bioengineering Center and the School of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA2 Oncology-Hematology Section, Health Sciences Center, University of Oklahoma, Oklahoma City, OK, USA3 Stephenson Cancer Center, ... [Published BMC - Jul 22 2014]
Entities: Cytosine, Purine, Nucleoside
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Oligomer conjugates of heteropentacyclic nucleosides

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. ... [Published Free Patents Online - Jul 15 2014]
Entities: Nucleoside, Invention
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom

Provided herein are novel base modified bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel pyrimidine bicyclic nucleosides are provided wherein each pyrimidine base is ... [Published Free Patents Online - Jul 15 2014]
Entities: Nucleoside, Pyrimidine, RNA
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Ribavirin Uptake into Human Hepatocyte HHL5 Cells Is Enhanced by Interferon-α via up-Regulation of the Human Concentrative Nucleoside Transporter (hCNT2)

Ribavirin is a broad spectrum antiviral that increases the response rate in chronic hepatitis C patients when administered in combination with IFNα. Ribavirin is a purine nucleoside derivative, transported into hepatocytes by nucleoside transporters. ... [Published Molecular Pharmaceutics - Jul 04 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

2′,4′-substituted nucleosides as antiviral agents

Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, ... [Published Free Patents Online - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Method and kit for determination of thymidine kinase activity and use thereof

A method and assay kit for determination of thymidine kinase (TK) activity in a biological sample, such as blood, serum, plasma, Cerebral Spinal Fluid (CSF), pleural fluid, ascites, tissues, cells and extracts thereof, is described. The method comprises ... [Published Free Patents Online - Jul 01 2014]

Quotes

"Our conjugate delivery platform - specifically utilizing GalNAc-siRNA conjugates - enables subcutaneous dosing of RNAi therapeutics with potent and durable effects and a wide therapeutic index. With our Enhanced Stabilization Chemistry (ESC) conjugates, we believe that once-monthly and possibly once-quarterly subcutaneous dosing regimens can be achieved in our clinical pipeline programs. Based on this progress, we believe that GalNAc-conjugates are now the industry-leading delivery approach for RNA therapeutics targeting liver-expressed genes, and this patent allowance will reinforce Alnylam's central role in value creation based on therapeutics linked to this technology."
..." said Dr Dominique Limet, CEO, ViiV Healthcare. "The treatment of HIV has come a long way, but it is essential that we continue to pursue effective novel treatment strategies that minimise toxicity while maximising tolerability and convenience to meet our objective of delivering advances in care and treatment for all people living with HIV."
"It is to be understood that both the foregoing general description and the following detailed description present embodiments of the disclosure and are intended to provide an overview or framework for understanding the nature and character of the disclosure as it is claimed. The description serves to explain the principles and operations of the claimed subject matter. Other and further features and advantages of the present disclosure will be readily apparent to those skilled in the art upon a reading of the following disclosure."

More Content

All (142) | News (126) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (1) | Press Releases (3)
sort by: Date | Relevance
Hepatitis B Treatment [Published eMedicine Health - 4 hours ago]
Alnylam receives notice of allowance for patent... [Published Individual.com - 4 hours ago]
ViiV Healthcare announces data from Phase III H... [Published Individual.com - 4 hours ago]
MEAD JOHNSON NUTRITION : "Nutritional Compositi... [Published 4 Traders - 10 hours ago]
A mushrooming debate [Published Global Times - Jul 30 2014]
IL-10 mediated by herpes simplex virus vector r... [Published 7thSpace - Jul 30 2014]
Bristol-Myers Squibb Company v. Teva Pharmaceut... [Published Lexology - Jul 30 2014]
Supporting activities of daily living [Published Free Patents Online - Jul 30 2014]
AIDS 2014: Dolutegravir Demonstrates Good Effic... [Published HIV and Hepatitis.com - Jul 29 2014]
RSV Research Breakthrough to Help Infected Chil... [Published RT Magazine - Jul 29 2014]
ONLINE FIRST: Metastatic Colorectal Cancer: TAS... [Published Oncology Times - Jul 28 2014]
Forced mutations doom HIV [Published MIT News feed - Jul 28 2014]
Court Report - July 2014 #3 [Published JD Supra - Jul 28 2014]
acyclovir, Zovirax [Published MedicineNet.com - Jul 26 2014]
Resistance Mutations Persist in HIV DNA After 1... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
RSV research breakthrough to help infected chil... [Published EurekAlert! - Jul 24 2014]
BioCryst Bets on New Ebola Drug to Fight Bioter... [Published Xconomy - Jul 24 2014]
Findings from University of Alabama Provides Ne... [Published Wall Street Business Network - Jul 24 2014]
Findings from University of Alabama Provides Ne... [Published HispanicBusiness.com - Jul 24 2014]
Studies Conducted at University of North Caroli... [Published 4 Traders - Jul 24 2014]
Research Conducted at School of of Chemistry an... [Published HispanicBusiness.com - Jul 24 2014]
VERTEX PHARMACEUTICALS : Patent Issued for Proc... [Published 4 Traders - Jul 24 2014]
Raltegravir Not Better Than NRTIs for Refractor... [Published Diabetes Care - Jul 23 2014]
Patent Issued for Modulation of Line-1 Reverse ... [Published HispanicBusiness.com - Jul 23 2014]
Phase III Trial Shows Improved Survival With TA... [Published The ASCO Post - Jul 23 2014]
Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc. [Published JD Supra - Jul 23 2014]
AIDS 2014: Maraviroc Fails To Match Truvada for... [Published HIV and Hepatitis.com - Jul 23 2014]
Study Linked EBV to Arthritis; CBCD Reviews the... [Published PRWeb - Jul 23 2014]
GSK/Pfizer’s two-drug HIV regimen falls short i... [Published MedCity News - Jul 22 2014]
Nucleosides and oligonucleotides for studies on... [Published Free Patents Online - Jul 22 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Forced mutations doom HIV [Published MIT News feed - Jul 28 2014]
Fifteen years ago, MIT professor John Essigmann and colleagues from the University of Washington had a novel idea for an HIV drug. They thought if they could induce the virus to mutate uncontrollably, they could force it to weaken and eventually die ...
TriLink gets patents for new ligation technolog... [Published PBR - News - Jun 20 2014]
TriLink BioTechnologies (TriLink), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, has announced that it has been awarded patents in the US (8,728,725), Europe (EP 2451980) and New Zealand (597535) for their ...
TriLink Awarded Patents for Novel Ligation Tech... [Published Marketwire - Breaking News Releases - Jun 19 2014]
SAN DIEGO, CA--(Marketwired - Jun 19, 2014) - TriLink BioTechnologies ( TriLink ), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, today announced that it has been awarded patents in the US (8,728,725), Europe ...
TriLink to Open New GMP Facility Aimed at Early... [Published Marketwire - Breaking News Releases - May 21 2014]
SAN DIEGO, CA--(Marketwired - May 21, 2014) -  TriLink BioTechnologies ( TriLink ), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, today announced their new 2,000 square foot diagnostic and pharmaceutical ...
Expanded DNA alphabet provides more options for... [Published the Foresight Institute - May 15 2014]
Floyd E. Romesberg, associate professor at Scripps Research (Credit: The Scripps Research Institute) Long-time readers of Nanodot may remember the section of Chapter 15 of Nanosystems in which Drexler explores options for producing easier to ...
1 2 3

Press Releases

sort by: Date | Relevance
QED Connect Inc. Plans to Add World Class Scien... [Published GlobeNewswire: Acquisitions News - Jul 10 2014]
Chimerix Regains Worldwide Rights to CMX157 [Published GlobeNewswire: Advertising News - May 16 2014]
Idenix Pharmaceuticals Intends to Appeal Norway... [Published GlobeNewswire: Advertising News - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.